We are working towards the development of certified in vitro diagnostic tests that allow physicians to select the right treatment for each individual patient based on their activity in live tumours tissues. These tests will use the unique ability of Allcyte's Pharmacoscopy® platform to interrogate drug activity in individual patient tissues with demonstrated clinical translatability.


With plans to process 100,000s of patient samples per year, we envsion that Allcyte will build a unique data asset of phenotypic drug response in primary patient tissues. In connection with -omics and clinical annotations, this rich resource in the future can be mined for target, biomarker discovery and to guide the design of clinical trial.